Liposomes for Transmucosal Drug Delivery

Dear Colleagues,

Liposomes are safe and biocompatible vesicular nanosystems that can incorporate hydrophilic, hydrophobic and amphiphilic small molecules, as well as macromolecules, nanoparticulates, or bacterial and virus material. With different sizes and surface properties, these versatile vesicles have a huge potential as nanocarriers to overcome body barriers. Transmucosal administration is an alternative route for a great variety of medications. Ocular infections, glaucoma, macular degeneration, dry eye or corneal pain demand innovative medicines able to cross ocular barriers. Drug inhalation is a challenge for the systemic delivery of therapeutic proteins, as well as passive targeting for pulmonary diseases such as cancer or hypertension. Nose-to-brain delivery is proposed for treatment of Alzheimer’s, Huntington’s or Parkinson´s diseases. The development of sustained local delivery at the buccal, nasal, vaginal, gastrointestinal or vesical cavity is in high demand for many drugs. On top of that, liposomal vectors for DNA, mRNA and other types of vaccines intended for transmucosal delivery are highly sought after. Liposomal formulations may incorporate a great variety of active compounds and transport them from the mucous membrane to the target site.

This Special Issue aims to highlight current progress in the development of liposomes for the transmucosal delivery of drugs and vaccines.

Prof. Dr. Amparo Sánchez Navarro
Dr. María José de Jesús Valle
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.